OPCHHealthcare · Medical Care FacilitiesThe 11 Wall Street analysts covering Option Care Health, Inc. hold a median 12-month price target of $32 — +3.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Option Care Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (51): The shares have been drifting down relative to others.
Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OPCH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | UBS | Downgrade | Neutral | $39 → $32 |
| 7 Oct 2026 | Barrington Research | Downgrade | Market Perform | — |
| 7 Oct 2026 | Citizens | Downgrade | Market Perform | — |
| 7 Oct 2026 | Jefferies | Downgrade | Hold | $28 → $32 |
| 7 Oct 2026 | JP Morgan | Downgrade | Neutral | $33 |
| 7 Oct 2026 | William Blair | Downgrade | Market Perform | — |
| 30 July 2026 | Deutsche Bank | Downgrade | Hold | $26 → $24 |
| 30 July 2026 | Deutsche Bank | Downgrade | Hold | — |
| 17 July 2026 | Stephens & Co. | Downgrade | Equal-Weight | $30 → $24 |
| 17 July 2026 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 8 June 2026 | Goldman Sachs | Initiates | Neutral | $22 |
| 8 June 2026 | Goldman Sachs | Initiates | Neutral | — |
| 6 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 4 May 2026 | JP Morgan | Maintains | Overweight | — |
| 1 May 2026 | Barrington Research | Maintains | Outperform | — |
| 1 May 2026 | TD Cowen | Maintains | Hold | — |
| 1 May 2026 | UBS | Maintains | Buy | — |
| 16 Jan 2026 | Barrington Research | Maintains | Outperform | — |
| 13 Jan 2026 | Citizens | Reiterates | Market Outperform | — |
| 13 Jan 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPCH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Option Care Health, Inc. returned +14.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 72% of US stocks
Cheaper than 26% of US stocks
Cheaper than 25% of US stocks
Higher than 31% of US stocks
Higher than 43% of US stocks
Higher than 19% of US stocks
Higher than 57% of US stocks
Higher than 57% of US stocks
Higher than 76% of US stocks
Higher than 82% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Option Care Health, Inc. has a market value of $4.7B and an enterprise value of $5.7B.
Revenue in the twelve months to 30 June 2026: $5.7B. The latest quarter grew 1.9% year on year.
Net income over the same four quarters: $209.6M, a 3.7% net margin.
Diluted earnings per share, trailing twelve months: $1.33.
Free cash flow in the twelve months to 30 June 2026: $303.8M.
Option Care Health, Inc. spent $328.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 23.6×; forward P/E: 14.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Option Care Health, Inc. employs 8,000 people — $712K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Option Care Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Wohl & Fruchter LLP said it is investigating the fairness of the proposed sale of Option Care Health to CD&R and McKesson for $32.05 per share in cash.
Why it matters — The investigation concerns the terms of the proposed transaction, which may be relevant to OPCH shareholders following the sale.
Business Wire reports that SBS Law announced an opportunity for OPCH investors to join its fraud investigation involving Option Care Health, Inc.
Why it matters — OPCH watchers may want to note the reported investor fraud investigation.
Kahn Swick & Foti, LLC says it is investigating the adequacy of the price and process for the proposed sale of Option Care Health to CD&R and McKesson. Under the proposed terms, shareholders would receive $32.05 in cash per share.
Why it matters — OPCH shareholders may follow the investigation’s review of the proposed transaction’s consideration and process.
Benzinga’s headline says an analyst covering Option Care Health is no longer bullish, as part of a roundup of four Wednesday downgrades. The excerpt provides no analyst name or further details about the rating change.
Why it matters — The reported change in analyst outlook is relevant to OPCH watchers, though the excerpt does not specify the analyst’s revised rating or rationale.
Option Care Health was a big mover in the latest session, with higher-than-average trading volume. The item notes that recent earnings estimate revisions may not support continued near-term gains.
Why it matters — OPCH watchers may weigh the session’s strong move against the caution about earnings estimate revisions.
The 11 Wall Street analysts covering Option Care Health, Inc. have a median 12-month price target of $32, with estimates ranging from $23 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Option Care Health, Inc., 0 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Option Care Health, Inc. 85 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Option Care Health, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +3.0% from the last close, and Ticker Nerd's factor model ranks Option Care Health, Inc. 85 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Option Care Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPCH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $33 over the next 12 months.
Option Care Health, Inc. returned +14.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Option Care Health Inc. is a healthcare services company that provides home and alternate site infusion therapy across the United States.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "OPCH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Option Care Health to CD&R and McKesson". Wohl & Fruchter LLP said it is investigating the fairness of the proposed sale of Option Care Health to CD&R and McKesson for $32.05 per share in cash.
Option Care Health Inc. is a healthcare services company that provides home and alternate site infusion therapy across the United States. The company delivers medications and clinical support for patients who need intravenous or injectable treatments outside the hospital, including therapies for infections, immune deficiencies, chronic inflammatory disorders, nutrition support, and other acute or chronic conditions. Its services combine pharmacy coordination, nursing care, treatment monitoring, and care coordination to support patients in home settings and ambulatory infusion suites. Option Care Health works with physicians, hospitals, payers, and other referral sources to manage complex infusion regimens through a national network of pharmacies and infusion locations. The company plays an important role in post-acute care by helping shift appropriate treatment to lower-acuity settings while maintaining clinical oversight and continuity of care.
CEO Mr. John Charles Rademacher · 8,000 employees · United States · https://optioncarehealth.com
